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Introduction
 Human CD93, with a molecular weight of about 90-100 
kDa, is a heavily O-glycosylated type I transmembrane 
protein consisting of unique C-type lectin domains. CD93 is 
selectively expressed on myeloid cell lineages (monocytes 
and granulocytes),endothelial cells and hematopoietic stem 
cells1-5).In addition, it is also co-expressed on naive T 
lymphocytes (CD4+CD45RA+cells) of neonatal umbilical 
cord blood cells (UCBCs), but not on normal adult 
peripheral blood cells (PBCs)6, 7). In relation to its 
biological functions, CD93 is reported to play critical 
roles in the exclusion of apoptotic cells8) and in 
angiogenesis9,10).
 CD93 has been demonstrated to be shed/released from 
the surface of activated human monocytes and 
granulocytes (mainly neutrophils) in vitro , and is 
therefore detected in a soluble form in the serum 
(sCD93)11). In particular, sCD93 shedding/release has 
been shown in vitro to occur in response to inflammatory 
mediators such as tumor-necrosis factor-α (TNF-α), 
interleukin-6 (IL-6), IL-8, endotoxin lipopolysaccharide 
(LPS) and the protein kinase C (PKC) activator phorbol 
myristate acetate (PMA)11,12). Furthermore, sCD93 has 
also been commonly detected in human serum/plasma 
of normal healthy adults. Enhanced sCD93 shedding/
release, with elevation of the serum or synovial fluid 
concentrations of sCD93, has also been demonstrated in 
certain clinical conditions 5,13,14).
 Recently, existence of a correlation between the serum 
sCD93 and serum cystatin C (cysteine protease 
inhibitor) concentrations was reported in both normal 
healthy adults and patients with myocardial infarction15). 
On the other hand, it has been reported that as cystatin 
C is filtered out of the blood by the kidneys, it may be a 
better marker of the glomerular filtration rate than the 
blood urea nitrogen (BUN) or serum creatinine16,17). 
However, the correlations of the serum concentrations 
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participation in this study.
Processing of the blood and serum samples
 Blood samples of patients with chronic renal failure 
(CRF) (5 males and 9 females; age 71.7 ± 11.5 yr) were 
obtained from Ogawa Clinic of Urology (Nobeoka-city, 
Miyazaki). The diagnosis of CRF was established by 
conventional, clinical and histological criteria. Normal 
healthy control blood samples (5 males and 5 females; 
age 41.0 ± 11.3 yr) were obtained from normal healthy 
volunteers. All serum samples were prepared using the 
standard method and the sera were stored at -80℃ 
until use.
Measurement of the soluble form of CD93 
(sCD93) in the serum
 EIA plates (Sumitomo Co., Tokyo) were coated with 
500 ng/mL of CD93 mAb (mNI-11) in carbonate-
bicarbonate buffer (0.01 M NaCO3, 0.035 M NaHCO3, 
pH9.6) for 24 hr at 4℃ . The wells were washed four 
times with phosphate-buffered saline (PBS) containing 
0.05% Tween-20 (PBST) and blocked with PBST 
containing 2% BSA (BSA-PBST) for 60 min at room 
temperature. Thereafter, the wells were washed three 
times with PBST. Sera (x 100 dilution with 0.1% BSA-
PBST; 50 μL) and biotin-conjugated CD93 mAb (X-2) (x 
2,500 dilution with 0.1% BSA-PBST; 50 μL) were then 
added to each well, followed by incubation for 60 min at 
room temperature with shaking. A recombinant protein 
o f  t h e CD93 mo l e c u l e (TP306980)  (O r i G en e 
Technologies, Inc.) was added to each well as a positive 
control or as a CD93 standard. The wells were washed 
eight times with PBST, followed by addition of HRPOD-
conjugated streptavidin (x 5,000 dilution with 0.1% BSA-
PBST; 100 μL) to each well and incubation of the wells 
for 30 min at room temperature with shaking. The 
wells were then washed 10 times with PBST, followed 
by addition of the substrate-chromogen (TMB; Cosmo 
Bio Co.; 100 μL) to each well and incubation for 10 min 
at room temperature with gentle shaking. The reaction 
was stopped by the addition of 0.5 M-HCl (100 μL), and 
the optical density (O.D.) was read at 450 nm using a 
multichannel EIA-microplate reader (TOSHO Co.). The 
of sCD93 with those of serum cystatin C or other 
common renal function markers such as the BUN and 
serum creatinine in patients with chronic renal failure 
(CRF) remain very poorly understood. CRF, also known 
as chronic kidney disease (CKD), is associated with a 
progressive loss of renal function over a period of 
months or years. Often, CRF is diagnosed as a result of 
screening of people with some risk factors for kidney 
damage, such as high blood pressure or diabetes 
mellitus18). In particular, this disease is often identified 
after it has led to one of its complications, such as 
cardiovascular disease, anemia or pericarditis19). 
Therefore, a new biomarker that would allow a precise 
and timely diagnosis of CRF is desired.
 As described above, in this clinical study, to analyze the 
significance of sCD93 in renal function impairment, we 
examined the serum concentrations of sCD93 in patients 
with CRF as compared with those in normal healthy 
controls by an originally constructed enzyme-linked 
immunoassay (EIA) using a CD93 monoclonal antibody 
(mAb) (mNI-11) established in our laboratories2,6,7,20).
Materials and Methods
Antibodies and reagents
 A CD93 monoclonal antibody (mAb) (mNI-11; mouse 
IgG1)2,6,7,20) was established in our laboratories. Enzyme 
immunoassay (EIA) kits for interleukin-6 (IL-6) and 
vascular endothelial growth factor (VEGF) were 
purchased from MBL Co. (Nagoya, Japan) and IBL Co. 
(Gunma, Japan), respectively. A biotin-conjugated CD93 
mAb (X-2; mouse IgG1) and horseradish peroxidase 
(HRPOD)-conjugated streptavidin were purchased from 
Cosmo Bio Co. (Tokyo, Japan). Recombinant CD93 
protein (TP306980) was purchased from OriGene 
Technologies, Inc. (USA). An EIA kit for cystatin C was 
purchased from R&D Systems (Minneapolis, MN, USA).
Ethics statement
 The study protocol was approved by the institutional 
review board (IRB) of Kyushu University of Health and 
Welfare and IRB number was 14-009. Informed consent 
was obtained from all the donors prior to their 
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healthy controls (38.84 ± 30.50 vs. 22.44 ± 8.94 pg/mL) 
(Fig.2).
 Next, we examined the serum concentrations of sCD93 
and cystatin C in the patients with CRF and normal 
healthy controls. As shown in Figure 3, the serum 
concentrat ions of sCD93 and cystat in C were 
significantly higher (P < 0.01) in the patients with CRF 
than in the normal healthy controls (sCD93: 1.61 ± 0.60 
vs. 0.66 ± 0.08 ng/mL; cystatin C: 2.06 ± 1.19 vs. 0.75 
± 0.08 ng/mL).
 Finally, we analyzed the correlations between the 
serum sCD93 concentrations and the BUN, serum 
creatinine, and serum cystatin C. As shown in Figure 4, 
the serum concentrations of  sCD93 were strongly 
correlated with the BUN (r = 0.797, P < 0.001), serum 
creatinine (r = 0.784, P < 0.001) and serum cystatin C (r 
= 0.913, P < 0.001) ; interestingly, the strongest 
correlation was observed for the serum cystatin C.
 Cystatin C, with a molecular weight of about 13 kDa, is 
a housekeeping enzyme belonging to the cystatin 
superfamily. Cystatin C is produced in all cells and 
tissues and is present in all biological fluids, and is an 
important extracellular cysteine protease inhibitor that 
functions to protect various cells throughout the body 
against the onslaught of multiple foreign antigens21,22). 
Meanwhile, its low molecular weight allows it to be 
freely filtered by the glomerular membrane in the 
kidney and its concentration in the blood has been 
reported to be correlated with the glomerular filtration 
rate16). The serum level of cystatin C is independent of 
the weight and height, muscle mass, age and sex. Thus, 
serum cystatin C may be a better marker of the 
glomerular filtration rate and kidney function than the 
serum creatinine, which is currently the most 
commonly measured parameter of kidney function17,18). 
The strong correlation between the serum sCD93 and 
cystatin C concentrations may suggest that the serum 
sCD93 level may be a better marker of the glomerular 
filtration rate than the BUN or serum creatinine. 
The re f o r e , t h e s e f i nd i ng s sugge s t t h a t t h e 
measurement of sCD93 may be useful for analyzing the 
renal function.
 The detailed mechanism(s) underlying the elevated 
concentrations of sCD93 in the sera of patients with 
CRF remains unclear at the present time. However, we 
experiment was repeated five times.
Measurement of IL-6, VEGF and cystatin C in the 
serum
 The measurement of IL-6, VEGF and cystatin C in the 
serum samples was performed using an IL-6 detection 
EIA kit, VEGF detection kit and cystatin C detection 
kit, respectively. Each of the experiments was repeated 
three times.
Measurement of BUN and serum creatinine
 Measurement of BUN and creatinine in the serum 
samples was performed by outsourcing the laboratory 
examination to a Special Reference Laboratory (SRL). 
Each experiment was repeated three times.
Statistical analysis
 Data are expressed as mean ± standard deviation 
(SD). The statistical analysis was performed using an 
unpaired Student’ s t-test. Pearson’ s correlation was 
used for studying the correlations of the serum sCD93 
concentrations with the BUN, serum creatinine and 
serum cystatin C. Differences at P < 0.05 were 
considered to indicate significance.
Results and Discussion
 First of all, we examined the concentrations of the 
well-known renal function markers such as BUN and 
serum creatinine in patients with CRF and normal 
healthy controls. As expected and shown in Figure 1, 
the levels of these biomarkers were significantly higher 
(P < 0.05) in the patients with CRF than in the normal 
healthy controls (BUN: 32.20 ± 21.30 vs. 14.96 ± 2.63 
mg/dL; serum creatinine: 2.18 ± 1.77 vs. 0.72 ± 0.12 
mg/dL). In addition, the serum levels of IL-6 were also 
significantly higher (P < 0.05) in the patients with CRF 
than in the normal healthy controls (6.69 ± 6.40 vs. 1.83 
± 1.06 pg/mL ) (F i g .2) ,  s ugge s t i ng e l eva t ed 
inflammatory responses in CRF patients. However, the 
serum level of VEGF was not significantly different (P 
= 0.115) between the patients with CRF and the normal 
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are needed to identify the precise mechanism(s) of 
these findings at the cellular and molecular levels.
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Figure 2.  Concentrations of the serum IL-6 and serum VEGF in patients with CRF (n=14) and normal healthy controls (n=10). The 
measurements were performed using EIA kits (See Materials and Methods for details). Each measurement was repeated four 
times.  *P < 0.05 (Normal vs. CRF). **P = 0.115 (Normal vs. CRF).
Figure 1.  Concentrations of the BUN and serum creatinine in patients with CRF (n=14) and normal healthy controls (n=10). The 
measurements were performed by a routine procedure (outsourced laboratory examination). Each measurement was repeated three 
times. * P < 0.05 (Normal vs. CRF).
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Figure 4.  Analysis of the correlations of the serum concentrations of sCD93 and the BUN, serum creatinine, and serum cystatin 
C in patients with CRF. A: Correlation between serum sCD93 and BUN (r = 0.797, P < 0.001) in all CRF patients. B: Correlation 
between serum sCD93 and serum creatinine (r = 0.784, P < 0.001) in all CRF patients. C: Correlation between serum sCD93 
and serum cystatin C (r = 0.913, P < 0.001) in all CRF patients.
Figure 3.  Concentrations of the serum sCD93 and serum cystatin C in patients with CRF (n=14) and normal healthy controls 
(n=10). The measurements were performed using EIA kits (See Materials and Methods for details). Each measurement was 
repeated four times. *P < 0.01 (Normal vs. CRF).
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要　旨
　慢性腎不全（CRF）患者における可溶性CD93（sCD93）の血清レベルを自主開発した抗ヒトCD93抗体
（mNI-11）とオリジナル構築酵素抗体法（EIAキット）を用いて検討した。その結果、CRF患者血清中の
sCD93は健康人と比較して有意に高値を示した。また、血清中インターロイキン-6（IL-6）もCRF患者は健
康人に比較して有意に高値を示した。CRF患者血清中のsCD93と腎機能マーカーである尿素窒素、血清ク
レアチニン、血清シスタチンCとの相関を解析したところ、いずれも強い相関を示した。特に血清シスタ
チンCとはより強い相関を示した（r＝0.903、P＜0.001）。以上の結果から、CRF患者血清中のsCD93は、
特に血清シスタチンCとの相関性がより強いことから、早期の腎障害を検出する新規のバイオマーカーに
なることがわかった。
キーワード：バイオマーカー，慢性腎不全，血清シスタチンC，可溶性CD93分子
